HMPL-523

Phase 3

Hutchmed (HCM)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

HCMPDUFA$2.5B

Phase 3

FDA PDUFA Date Sovleplenib (priority review)

HMPL-523• Warm Antibody Autoimmune Hemolytic Anemia

Dec 2026~AI-detected

Source

00%

Competitive Landscape

0 competitors in Primary Immune Thrombocytopenia (ITP)

View Full Landscape

Drug Information

Target Indication

Primary Immune Thrombocytopenia (ITP)

Clinical Trial

NCT05029635

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HCM

Hutchmed

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

HMPL-306 RegimenPhase 3

Acute Myeloid Leukemia

Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and GemcitabinePhase 3

Metastatic Pancreatic Cancer

fruquintinib+sintilimabPhase 3

Advanced Renal Cell Carcinoma

HMPL-453Phase 3

Advanced Intrahepatic Cholangiocarcinoma

fruquintinibPhase 3

Advanced Endometrial Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts